Prestige Consumer Healthcare Inc. (PBH) Q4 2025 10-Q Quarterly Report
Prestige Consumer Healthcare Inc. (PBH) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 5, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Prestige Consumer Healthcare Inc. Q4 2025 10-Q Analysis
Risk Factors
- • New risk: Acquisition of Pillar5 Pharma in Dec 2025 triggered increased borrowing of $40M under asset-based revolver to partially fund deal
- • Most materially updated risk: Supply chain disruptions causing product shortages, especially Eye & Ear Care, negatively impacting sales and operations
Prestige Consumer Healthcare Inc. Q4 2025 Quarterly FinancialsXBRL
Revenue
$283M
▼ -2.4% YoY▲ +3.4% QoQ
Net Income
$47M
▼ -23.5% YoY▲ +10.6% QoQ
Gross Margin
55.5%
▲ +5bp YoY▲ +22bp QoQ
Operating Margin
29.1%
▼ -257bp YoY▲ +4bp QoQ
Net Margin
16.5%
▼ -455bp YoY▲ +108bp QoQ
ROE
2.6%
▼ -86bp YoY
Total Assets
$3.5B
▲ +5.0% YoY
EPS (Diluted)
$0.97
▼ -20.5% YoY▲ +12.8% QoQ
Operating Cash Flow
$78M
▲ +20.3% YoY▲ +36.2% QoQ
Source: XBRL data from Prestige Consumer Healthcare Inc. Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Prestige Consumer Healthcare Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.